EVOKE Plus - NN6536-4725 | A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer’s disease (EVOKE plus). | Neurology | Sean Kennelly |
EVOKE - NN6535-4730 | A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) | Neurology | Sean Kennelly |
MK 3475-811-1513 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811) | Oncology | Fergal Kelleher |
CA209-77T | A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination with Intravesical BCG versus Standard of Care BCG Alone in Participants with High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment with BCG | Oncology | Fergal Kelleher |
MK 3475-966 | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma | Oncology | Fergal Kelleher |
MK 3475-937-0499 | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinomaand Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) | Oncology | Fergal Kelleher |
MIRANDA Study | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallelgroup, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) | Respiratory | Patrick Mitchell |
MK 7339-002-1652 | A phase II study of Olaparib Monotherapy in participants with previously treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) positive advanced cancer. | Oncology | Ray McDermott |
Add Aspirin | A phase III double blind placebo controlled randomised trial assessing the the effects of aspirin on disease recurrnce and survival after primary therapy in common non-metastatic solid tumours | Oncology | Ray McDermott |
MK 3475-859-1202 | A Phase III randomised double blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first line treatment in partcipants with HER2 negetive previously untreated unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859) | Oncology | Ray McDermott |
CA209-67T | A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy | Oncology | Ray McDermott |
MK 3475-641 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) | Oncology | Ray McDermott |
MK 3475-866 | Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-866)” MK-3475-866-710 | Oncology | Ray McDermott |
MK 3475-905-734 | A phase III randomised study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible participants with muscle invasive bladder cancer (KEYNOTE - 905) | Oncology | Ray McDermott |
MK 3475-921 | Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE- 921) | Oncology | Ray McDermott |
MK 7339-010 | A phase III randomised open label study of Pembrolizumab (MK-3475) plus Olaparib versus Abiraterone Acetate or Enzalutamide in participants with metastatic castration resistant prostate cancer (MCRPC) who are unselected for Homologous recombination repair defects and have failed prior treatment with one next generation Hormonal Agent (NHA) and chemotherapy (KEYLINK-010) | Oncology | Ray McDermott |
MK 3475-991-1301 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) | Oncology | Ray McDermott |
MK 6482-013 | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | Oncology | Ray McDermott |
Wayfind-R | A REGISTRY TO COLLECT THE NATURAL HISTORY OF SOLID TUMOUR CANCERS IN PATIENTS PROFILED WITH A NEXT GENERATION SEQUENCING TEST (WAYFIND-R) | Oncology | Ray McDermott |
MK 5684-003 | A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy | Oncology | Ray McDermott |
MK 3475-B61-1600 | A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Nonclear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61) | Oncology | Ray McDermott |
MK 6482-012-6100 | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Oncology | Ray McDermott |
MK 6482-011-3200 | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy: “MK6482-011-3200 | Oncology | Ray McDermott |
DESTINY-Gastric04 | A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | Oncology | Ray McDermott |
Imvigor BO42843 | A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA-POSITIVE FOLLOWING CYSTECTOMY | Oncology | Ray McDermott |
Peace 6 - Vulnerable | A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents | Oncology | Ray McDermott |
MK 3475-365-3300 | “Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE- 365)” MK-3475-365-3300 | Oncology | Ray McDermott |
MK 6482-022 | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy ” MK-6482-022-1402 | Oncology | Ray McDermott |
MK 5684-004 | A Phase 3 Randomized, Open-label Study of MK5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) | Oncology | Ray McDermott |
HOVAN 156 AML/AMLSG 28-18 | A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patient’s with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy | Oncology | Ronan Desmond |
ARGX-113-2005 | A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Oncology | Ronan Desmond |
